|
1
|
Rotter A and de Oliveira ZNP: Infantile
hemangioma: Pathogenesis and mechanisms of action of propranolol. J
Dtsch Dermatol Ges. 15:1185–1190. 2017. View Article : Google Scholar
|
|
2
|
Storch CH and Hoeger PH: Propranolol for
infantile haemangiomas: Insights into the molecular mechanisms of
action. Br J Dermatol. 163:269–274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schwartz RA, Sidor MI, Musumeci ML, Lin RL
and Micali G: Infantile haemangiomas: A challenge in paediatric
dermatology. J Eur Acad Dermatol Venereol. 24:631–638. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harbi S, Wang R, Gregory M, Hanson N,
Kobylarz K, Ryan K, Deng Y, Lopez P, Chiriboga L and Mignatti P:
Infantile hemangioma originates from a dysregulated but not fully
transformed multipotent stem cell. Sci Rep. 6:358112016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Léauté-Labrèze C: Infantile hemangioma:
Update and treatment. Arch Pediatr. 20:517–522. 2013.(In French).
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Léauté-Labrèze C, Dumas de la Roque E,
Hubiche T, Boralevi F, Thambo JB and Taïeb A: Propranolol for
severe hemangiomas of infancy. N Engl J Med. 358:2649–2651. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raphael MF, Breur JM, Vlasveld FA, Elbert
NJ, Liem YT, Kon M, Breugem CC and Pasmans SG: Treatment of
infantile hemangiomas: Therapeutic options in regard to side
effects and adverse events-a review of the literature. Expert Opin
Drug Saf. 15:199–214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wasserman JD, Mahant S, Carcao M, Perlman
K and Pope E: Vincristine for successful treatment of
steroid-dependent infantile hemangiomas. Pediatrics.
135:e1501–e1505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamashita-Kashima Y, Fujimoto-Ouchi K,
Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H and Mori K: Biomarkers
for antitumor activity of bevacizumab in gastric cancer models. BMC
Cancer. 12:372012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pourazizi M, Kabiri S and Abtahi-Naeini B:
Intralesional bevacizumab (Avastin®) as a novel addition
to infantile hemangioma management: A medical hypothesis. J Res
Pharm Pract. 6:190–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stiles J, Amaya C, Pham R, Rowntree RK,
Lacaze M, Mulne A, Bischoff J, Kokta V, Boucheron LE, Mitchell DC
and Bryan BA: Propranolol treatment of infantile hemangioma
endothelial cells: A molecular analysis. Exp Ther Med. 4:594–604.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hein M and Graver S: Tumor cell response
to bevacizumab single agent therapy in vitro. Cancer Cell Int.
13:942013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chao MW, Lai MJ, Liou JP, Chang YL, Wang
JC, Pan SL and Teng CM: The synergic effect of vincristine and
vorinostat in leukemia in vitro and in vivo. J Hematol Oncol.
8:822015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fischer-Fodor E, Mot A, Deac F, Arkosi M
and Silaghi-Dumitrescu R: Towards hemerythrin-based blood
substitutes: Comparative performance to hemoglobin on human
leukocytes and umbilical vein endothelial cells. J Biosci.
36:215–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ceballos-Torres J, Virag P, Cenariu M,
Prashar S, Fajardo M, Fischer-Fodor E and Gómez-Ruiz S: Anti-cancer
applications of titanocene-functionalised nanostructured systems:
An insight into cell death mechanisms. Chemistry. 20:10811–10828.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ji Y, Li K, Xiao X, Zheng S, Xu T and Chen
S: Effects of propranolol on the proliferation and apoptosis of
hemangioma-derived endothelial cells. J Pediatr Surg. 47:2216–2223.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamy S, Lachambre MP, Lord-Dufour S and
Béliveau R: Propranolol suppresses angiogenesis in vitro:
Inhibition of proliferation, migration, and differentiation of
endothelial cells. Vascul Pharmacol. 53:200–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bouis D, Hospers GA, Meijer C, Molema G
and Mulder NH: Endothelium in vitro: A review of human vascular
endothelial cell lines for blood vessel-related research.
Angiogenesis. 4:91–102. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zou HX, Jia J, Zhang WF, Sun ZJ and Zhao
YF: Propranolol inhibits endothelial progenitor cell homing: A
possible treatment mechanism of infantile hemangioma. Cardiovasc
Pathol. 22:203–210. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ou JM, Yu ZY, Qiu MK, Dai YX, Dong Q, Shen
J, Wang XF, Liu YB, Quan ZW and Fei ZW: Knockdown of VEGFR2
inhibits proliferation and induces apoptosis in hemangioma-derived
endothelial cells. Eur J Histochem. 58:22632014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ritter MR, Butschek RA, Friedlander M and
Friedlander SF: Pathogenesis of infantile haemangioma: New
molecular and cellular insights. Expert Rev Mol Med. 9:1–19. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pan WK, Li P, Guo ZT, Huang Q and Gao Y:
Propranolol induces regression of hemangioma cells via the
down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Pediatr Blood
Cancer. 62:1414–1420. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tu JB, Ma RZ, Dong Q, Jiang F, Hu XY, Li
QY, Pattar P and Zhang H: Induction of apoptosis in infantile
hemangioma endothelial cells by propranolol. Exp Ther Med.
6:574–578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Margolin K, Gordon MS, Holmgren E,
Gaudreault J, Novotny W, Fyfe G, Adelman D, Stalter S and Breed J:
Phase Ib trial of intravenous recombinant humanized monoclonal
antibody to vascular endothelial growth factor in combination with
chemotherapy in patients with advanced cancer: Pharmacologic and
long-term safety data. J Clin Oncol. 19:851–856. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jain RK: Tumor angiogenesis and
accessibility: Role of vascular endothelial growth factor. Semin
Oncol. 29 (6 Suppl 16):S3–S9. 2002. View Article : Google Scholar
|
|
26
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kabbinavar F, Irl C, Zurlo A and Hurwitz
H: Bevacizumab improves the overall and progression-free survival
of patients with metastatic colorectal cancer treated with
5-fluorouracil-based regimens irrespective of baseline risk.
Oncology. 75:215–223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Y, Tian H, Blobe GC, Theuer CP,
Hurwitz HI and Nixon AB: Effects of the combination of TRC105 and
bevacizumab on endothelial cell biology. Invest New Drugs.
32:851–859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hayot C, Farinelle S, De Decker R,
Decaestecker C, Darro F, Kiss R and Van Damme M: In vitro
pharmacological characterizations of the anti-angiogenic and
anti-tumor cell migration properties mediated by
microtubule-affecting drugs, with special emphasis on the
organization of the actin cytoskeleton. Int J Oncol. 21:417–425.
2002.PubMed/NCBI
|
|
30
|
Anguissola S, Garry D, Salvati A, O'Brien
PJ and Dawson KA: High content analysis provides mechanistic
insights on the pathways of toxicity induced by amine-modified
polystyrene nanoparticles. PLoS One. 9:e1080252014. View Article : Google Scholar : PubMed/NCBI
|
